Examkin

Soru

Zorluk: ZorMonitoring and Treatment Evaluation

A 32-year-old woman with relapsing-remitting multiple sclerosis is evaluated in the neurology clinic. She has experienced two clinical relapses over the past year, and her latest magnetic resonance imaging reveals three new gadolinium-enhancing periventricular lesions despite full adherence to interferon beta-1a therapy. The physician and patient agree to transition her disease-modifying therapy to oral fingolimod. Her past medical history is otherwise unremarkable. She takes no other medications. Vital signs are within normal limits. Physical examination demonstrates mild residual weakness in the right lower extremity. Which of the following baseline evaluations or monitoring parameters are explicitly required prior to or during the initiation of this specific medication? (Select all that apply)

  1. Baseline electrocardiogram and continuous cardiac observation for the first doseCevap
  2. Baseline ophthalmologic examination to evaluate the maculaCevap
  3. C
    Serum John Cunningham (JC) virus antibody assay
  4. D
    Transthoracic echocardiography to assess left ventricular function
  5. E
    Thiopurine methyltransferase (TPMT) enzyme activity testing

Cevap

The required baseline evaluations for initiating fingolimod are a baseline electrocardiogram with first-dose continuous cardiac observation, and a baseline ophthalmologic examination encompassing the macula.
Fingolimod is a sphingosine 1-phosphate (S1P) receptor modulator. It sequesters lymphocytes in lymph nodes, preventing them from contributing to autoimmune inflammation. However, S1P receptors are also located in cardiac tissue and the eye. Activation of cardiac S1P receptors transiently slows the heart rate and alters atrioventricular conduction, mandating a baseline electrocardiogram and a minimum of 6 hours of continuous cardiac observation during the first dose. Furthermore, the drug increases vascular permeability in the eye, creating a significant risk for macular edema. Therefore, standard clinical guidelines require a comprehensive baseline ophthalmologic examination encompassing the macula.

Adım Adım Çözüm

1
Identify the newly prescribed medication and its drug class.
The medication is fingolimod, a sphingosine 1-phosphate (S1P) receptor modulator used for multiple sclerosis.
Understanding the mechanism of action is crucial for anticipating specific adverse effects that dictate monitoring protocols.
2
Recall the acute toxicities associated with the initiation of S1P receptor modulators.
Fingolimod causes a transient, sometimes severe decrease in heart rate and atrioventricular conduction delays immediately following the first dose.
This physiological effect necessitates mandatory baseline electrocardiography and at least 6 hours of continuous clinical and cardiac observation when the first dose is administered.
3
Recall the insidious or delayed organ-specific toxicities associated with the drug.
Fingolimod increases the risk of fingolimod-associated macular edema (FAME).
This specific risk requires a baseline ophthalmologic evaluation focusing on the macula prior to initiation, and a follow-up examination 3 to 4 months later.
4
Differentiate these requirements from monitoring parameters used for other MS biologics.
JC virus testing is excluded because it applies to natalizumab. Echocardiography and TPMT testing are excluded as they apply to entirely different classes of drugs (anthracyclines and thiopurines, respectively).
Ensures the selected monitoring parameters are strictly specific to the pharmacotherapy presented in the vignette.

Anahtar Kavram

Fingolimod initiation requires strict cardiovascular monitoring (baseline ECG and 6-hour first-dose observation) due to the risk of bradyarrhythmias, and a baseline ophthalmologic evaluation due to the risk of macular edema.
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru